| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: ≥98%
PF-04991532 is a novel, potent, hepatoselective glucokinase activator with EC50 of 80 and 100 nM in human and rat, respectively. It is able to ameliorate hyperglycemia without causing hepatic steatosis in diabetic rats. Hyperglycemia resulting from type 2 diabetes mellitus (T2DM) is the main cause of diabetic complications such as retinopathy and neuropathy. A reduction in hyperglycemia has been shown to prevent these associated complications supporting the importance of glucose control. Glucokinase converts glucose to glucose-6-phosphate and determines glucose flux into the β-cells and hepatocytes. Since activation of glucokinase in β-cells is associated with increased risk of hypoglycemia, selectively activating hepatic glucokinase would reduce fasting and postprandial glucose with minimal risk of hypoglycemia. Previous studies have shown that hepatic glucokinase overexpression is able to restore glucose homeostasis in diabetic models; however, these overexpression experiments have also revealed that excessive increases in hepatic glucokinase activity may also cause hepatosteatosis. PF-04991532 reduced plasma glucose concentrations independent of changes in insulin concentrations in a dose-dependent manner both acutely and after 28 days of sub-chronic treatment. During a hyperglycemic clamp in Goto-Kakizaki rats, the glucose infusion rate was increased approximately 5-fold with PF-04991532. This increase in glucose infusion can be partially attributed to the 60% reduction in endogenous glucose production. While PF-04991532 induced dose-dependent increases in plasma triglyceride concentrations it had no effect on hepatic triglyceride concentrations in Goto-Kakizaki rats. Interestingly, PF-04991532 decreased intracellular AMP concentrations and increased hepatic futile cycling. These data suggest that hepatoselective glucokinase activation may offer glycemic control without inducing hepatic steatosis supporting the evaluation of tissue specific activators in clinical trials.
| ln Vitro |
PF-04991532, a strong liver-selective glucokinase activator that is a Phase 2 clinical candidate, has an EC50 of 80 nM in humans and 100 nM in rats. Mechanistic studies conducted on recently obtained primary rat hepatocytes treated with PF-04991532 for 60 minutes revealed enhanced uptake of 2-[14C]-deoxyglucose (EC50 = 1.261 µM) and oxidation of glucose (EC50 = 5.769 µM). Additionally, PF-04991532 decreased the amount of glucose produced from 1-[14C]-lactate in a way that was dependent on dose (EC50 = 0.626 µM). PF-04991532 enhanced G6Pase expression in isolated rat hepatocytes as compared to cells treated with 100 nM glucagon alone. The combination of 25 mM glucose and 100 nM glucagon produced the greatest increase in G6Pase mRNA expression. Glucagon with PF-04991532 in this instance[1].
|
|---|---|
| ln Vivo |
To sustain hyperglycemia, PF-04991532 is administered once, increasing the rate of glucose infusion. Remarkably, rats given PF-04991532 for 19 days had hepatic triglycerides that were the same as those of GK rats given a vehicle, while having higher plasma triglycerides. The liver lipid contents in rats given PF-04991532 and the vehicle were found to be the same in another group that received treatment for 28 days (vehicle: 9.89±0.31; PF-04991532 100 mg/kg: 9.91±0.31). Lipogenic genes, including acetyl-CoA carboxylase (ACC), ATP citrate lyase (ACLY), and fatty acid synthase (FAS), were expressed more often in rats given PF-04991532 treatment [1].
|
| References |
[1]. Erion DM, et al. The hepatoselective glucokinase activator PF-04991532 ameliorates hyperglycemia without causing hepatic steatosis in diabetic rats. PLoS One. 2014 May 23;9(5):e97139
|
| Molecular Formula |
C18H19F3N4O3
|
|---|---|
| Molecular Weight |
396.363674402237
|
| CAS # |
1215197-37-7
|
| Related CAS # |
(R)-PF-04991532
|
| SMILES |
O=C(O)C1=CN=C(NC([C@@H](N2C=C(C(F)(F)F)N=C2)CC3CCCC3)=O)C=C1
|
| InChi Key |
GKMLFBRLRVQVJO-ZDUSSCGKSA-N
|
| InChi Code |
InChI=1S/C18H19F3N4O3/c19-18(20,21)14-9-25(10-23-14)13(7-11-3-1-2-4-11)16(26)24-15-6-5-12(8-22-15)17(27)28/h5-6,8-11,13H,1-4,7H2,(H,27,28)(H,22,24,26)/t13-/m0/s1
|
| Chemical Name |
(S)-6-(3-Cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic Acid
|
| Synonyms |
PF-04991532; PF 04991532; PF04991532; PF-4991532; PF4991532; PF 4991532.
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~315.37 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5230 mL | 12.6148 mL | 25.2296 mL | |
| 5 mM | 0.5046 mL | 2.5230 mL | 5.0459 mL | |
| 10 mM | 0.2523 mL | 1.2615 mL | 2.5230 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
 PF-04991532 regulates glucose metabolism in primary rat hepatocytes.
PF-04991532 effects on lipid metabolism and downstream hepatic metabolites. |
|---|
 PF-04991532 increased hepatic futile cycling.The effect of hepatic glucokinase activation on G6Pase (A) and the loss of positional labeling (B) in primary rat hepatocytes. (C). The increased substrate cycling decreased hepatic ATP concentrations as assessed by NMR (n = 6/group) (D) which in turn increased hepatic pAMPK/AMPK ratio (E) (n = 5/group).PLoS One.2014 May 23;9(5):e97139. |
 PF-04991532 improves glucose metabolism in rats.PF-04991532 increased the rate of glucose infusion in order to maintain hyperglycemia in Goto-Kakizaki rats (n = 6/group) (A) which can be attributed to the increased glucose disposal and decreased glucose production (n = 6/group) during steady state (B). PF-04991532 decreased plasma glucose in Goto-Kakizaki rats over 28 days of dosing (n = 6–8/group) (C) which was accompanied by an increase in plasma triglycerides at the highest dose (D).PLoS One.2014 May 23;9(5):e97139. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
